Satraplatin is the first orally administered platinum compound.
A Phase 3 study in Hormone Refractory Prostate Cancer began in September,
2003.
The primary endpoint of this study is time to disease progression.
Satraplatin was given fast track review designation by the FDA.

http://www.clinicaltrials.gov/ct/gui/show/NCT00069745
Exclusion Criteria:

   * More than one prior chemotherapy
   * Prior platinum containing compounds
   * Prior malignancy
   * Prior significant RT/radionuclide therapy
   * Major GI surgery or GI disease affecting absorption
   * Disease with contraindication to steroids
   * Brain metastases

http://www.medicalnewstoday.com/medicalnews.php?newsid=20470
Date: 01 Mar 2005
Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone versus
Prednisone alone in Patients with Hormone Refractory Prostate Cancer: EORTC
Genitourinary Tract Group Protocol #30972," by C.N. Sternberg et al, reports
the data from this study. Summary data from the study were presented at the
2003 Annual Meeting of the American Society of Clinical Oncology (ASCO).

The published study involved 50 randomized patients at 18 medical centers
and evaluated the use of satraplatin plus prednisone (N=27) versus
prednisone alone (N=23) for use as a first-line chemotherapy treatment for
HRPC.

Prednisone is a synthetic hormone often used to relieve some of the symptoms
of advanced prostate cancer. The study results showed that satraplatin
treatment significantly lengthened progression-free survival (p=0.023): The
median time to disease progression or death was 5.2 months for satraplatin
versus 2.5 months for the control arm. Additionally, at six months, 41% of
patients treated in the satraplatin arm were progression-free versus 22% of
patients in the control arm. The median overall survival time was 15 months
for patients treated in the satraplatin arm versus 12 months for patients in
the control arm, a numerical, but not statistically significant, difference.

This press release may contain projections or estimates relating to plans
and objectives relating to our future operations, products, or services;
future financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject to
risks and uncertainties, many of which are beyond our control. Actual
results could differ materially depending on a number of factors, including
the timing and effects of regulatory actions, the results of clinical
trials, the Company's relative success developing and gaining market
acceptance for any new products, and the effectiveness of patent protection.
There can be no guarantee that the SPARC trial will be completed in a timely
manner, if at all. Additionally, there can be no guarantee that satraplatin
will be approved for marketing in a timely manner, if at all.